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ABSTRACT
Smith-Magenis syndrome (SMS) is a type of mental retardation disorder
associated with a deletion of DNA from chromosome 17p11.2. It affects approximately
18,000 individuals in the US alone. Major phenotypes are associated with a mutation in
the Retinoic Acid-Inducible gene-1 (RAI1) and include: developmental delay, repetitive
behaviors, short stature, and hoarse voice. Studying the molecular mechanisms that lead
to SMS will help promote earlier detection of the disorder and will help develop a better
treatment plan for patients. The purpose of this project was to characterize the promoter
of RAI1. Studying the promoter of RAI1 will help determine the normal expression of the
gene providing clues to its normal function and providing insight into why the lack of
RAI1 leads to SMS.
The method used for characterizing promoter activity was the reporter gene assay.
The goal of this assay was to determine if previously cloned putative promoter fragments
contained any promoter activity. The putative RAI1 promoter was cloned in front of the
firefly luciferase reporter gene in the pGL3 plasmid and transiently transfected into the
mammalian cell line HEK293. The results we obtained suggest that the putative
promoter fragments did not contain any promoter activity.
In order to identify new putative promoter fragments, 5’RLM-RACE was used on
RNA isolated from HEK293 cells. The purpose of the procedure was to identify the 5’
end of the RAI1 transcript. If successfully cloned, the sequence of this fragment could be
used to align with the human genome sequence and locate potential promoter elements.
These studies are currently underway.
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INTRODUCTION
Smith-Magenis Syndrome. Smith-Magenis syndrome (SMS) is a type of mental
retardation disorder associated with a deletion of DNA from chromosome 17 or a
mutation of Retinoic Acid Inducible gene 1(RAI1). The birth incidence rate is
approximately 1/25,000 births. However, a higher incidence rate is suspected due to both
under-diagnosis and misdiagnosis of SMS [1, 2]. Smith-Magenis syndrome was first
discovered in 1986 by a group of researchers in Denver, Colorado [3]. Among those
researchers was Dr. Elsea who has since then continued her work with SMS at the
Medical College of Virginia in Richmond, VA. I did this project in collaboration with
Dr. Elsea and the members of her lab.
Physiological Significance. There are several phenotypes associated with SMS,
some more common than others. The most common phenotypes can be divided into two
groups: major developmental/behavioral phenotypes and physical phenotypes. The most
common developmental/behavioral phenotypes include developmental delay, repetitive
behaviors, self-injury, sleep disturbances, and hyperactivity. An example of a repetitive
behavior often seen with patients with SMS is self-hugging. The sleep disturbances seen
are due to an inverted circadian rhythm which causes increased wakefulness at night.
The most common physical phenotypes include short stature, hoarse voice, dental
anomalies, and oral/motor dysfunction. Examples of oral/motor dysfunction would
include decrease in tongue strength and an increase in drooling. Less common
phenotypes include seizures, heart defects, immune function abnormalities and
renal/urinary tract abnormalities [4] [5]. In one study involving multiple patients with
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SMS, it was found that certain phenotypes become more prominent with age. Some of
those phenotypes are hoarse voice, frontal prominence (large forehead), and coarsening
of facial features [6].
Causes of SMS. SMS was initially thought to be caused by a large scale alteration
in the expression of genes in the p arm of chromosome 17. There are two possible
mechanisms by which large scale alterations can occur. These methods are parental
imprinting and deletion of DNA. Parental imprinting is a type of epigenetic inheritance
that results in only one of the two inherited alleles being expressed. However, in an
experiment conducted in 1991, it was found that there were no differences in phenotypes
between both maternally and paternally derived chromosomes in SMS patients [6]. This
evidence ruled out the possibility of parental imprinting as a mechanism for producing
SMS [7]. Large scale deletions of DNA can occur in two ways. Deletion may occur by
unequal crossing over between repeated sequences producing an unbalanced DNA
rearrangement. Deletions can also occur spontaneously in the gonads of the parents
therefore not affecting the parents but affecting their children [8].
Studies of SMS patients have defined the SMS critical interval as the common
region on the p arm of chromosome 17 in which deletions causing the phenotypes
associated with SMS occur. The most common deletion is ~3.5Mb, found in about 75%
of patients [9]. Differences in phenotype and severity may be due to the differences in
deletion sizes and other genetic factors [7]. Smaller sized deletions are not as common
but have allowed for the refinement of the SMS critical interval. In 2003, a group of
researchers compressed the critical interval from 3.5 Mb to 950kb by using fluorescent in
situ hybridization (FISH), analysis [1]. FISH analysis uses fluorescent labeling of
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specific DNA sequences in order to determine if they are deleted or not. If the portion of
DNA that the probe binds to is not deleted then it will fluoresce. If the portion of DNA is
deleted then there will be no fluorescence. In 2005, a different group of researchers
further compressed the critical interval to 650kb, also by using FISH [10].
Within the 650kb critical interval, there are several candidate SMS genes (Table
1). DNA from patients that appear to have SMS but do not have a deletion were
sequenced to see if any of these candidate genes were mutated. All of these patients were
shown to have a mutation in Retinoic Acid Inducible gene 1 (RAI1). A mutation of the
RAI1 gene produces a nonfunctional or truncated protein which results in
haploinsufficiency [11] meaning that half of the amount of protein is not enough to
produce a normal phenotype. The majority of the features seen with SMS patients are
now attributed to haploinsufficiency of RAI1 because RAI1 mutations or deletions have
been found in all patients. Other deletions on chromosome 17p11.2 may cause some of
the less common phenotypes and contribute to phenotypic variability of SMS.
Table 1: Official names of genes found in the critical region on chromosome 17.
Gene short-hand
Official name of gene
RASD1
RAS dexamethasone-induced 1
PEMT
Phosphatidylethanolamine Nmethyltransferase
SMCR5
Smith-Magenis syndrome chromosome
region, candidate 5
RAI1
Retinoic acid induced 1
SREBF1
Sterol regulatory element binding
transcription factor 1
TOM1L2
Target of myb 1-like 2
ATPAF2
ATP synthase mitochondrial F1 complex
assembly factor 2
DRG2
Developmentally regulated GTP binding
protein 2
MYO15A
Myosin XVA
LLGL1
Lethal giant larvae homolog 1
FLI1
Friend leukemia virus integration 1
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SMCR7
TOP3A
SMCR8
SHMT1

Smith-Magenis syndrome chromosome
region, candidate 7
Topoisomerase (DNA) III alpha
Smith-Magenis syndrome chromosome
region, candidate 8
Serine hydroxymethyltransferase 1

In addition to its role in SMS, other functions of RAI1 have been identified. RAI1 may also play a role in schizophrenia and the age of onset of spinocerebellar ataxia
[12]. These two roles of RAI1, along with the role of RAI1 in SMS, indicate that RAI1
has a major effect on normal brain functioning. Furthermore, RAI1 has been shown to
have some anti-viral properties [13] [14].
In this project, the RAI1 promoter was studied. Studying the promoter of RAI1
will help determine the normal expression of the gene thereby providing clues to its
normal function. Furthermore, an understanding of the normal expression of RAI1 may
provide insight into why the lack of RAI1 leads to SMS.
Eukaryotic Gene Expression. In order for an organism to express a functional
protein from a gene, the specific DNA that encodes the protein must first be transcribed
into mRNA and then the mRNA must be translated into a functional protein. In
eukaryotes, there are four main steps to transcription. They are initiation, elongation,
termination, and post-RNA processing. Initiation is when RNA polymerase II binds to the
promoter region of the DNA. Elongation is the process of forming the RNA transcript.
Termination involves the release of the RNA transcript and the RNA polymerase from
the DNA template. Pre-RNA processing refers to further modification of the RNA
transcript after or during transcription that is necessary for translation of the RNA into a
protein [8].
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This project will focus on the RAI1 promoter and the initiation of transcription. A
promoter is a section of DNA important in initiation of transcription because it serves as
a recognition sequence for the attachment of the preinitiation complex. The preinitiation
complex that binds to the promoter region includes general transcription factors (GTFs),
coactivators, corepressors, and RNA polymerase II [8]. There are four specific portions
of the promoter that are of importance in the binding of GTFs and
coactivators/corepressors. They include the TATA box, the initiator element, the
downstream core promoter element, and the TFIIB recognition element. The TATA box
is the binding site of the TATA binding protein (TBP). The initiator element directly
overlaps the transcription start site and performs the same functions as the TATA box
including helping with the formation of the preinitiation complex. The downstream core
promoter element is a seven nucleotide sequence found about 30bp downstream of the
transcription start site. This element is particularly important for TATA-less promoters.
The TFIIB recognition element is a sequence specifically for the binding of TFIIB.
Coactivators and corepressors serve to either activate or repress transcription by binding
to certain places on the DNA [15].
There are two general types of promoters found within cells. They include
promoters with a TATA-box and promoters that don’t possess a TATA-box. Although
TBP usually binds to the TATA sequence, it can bind to the DNA in TATA-less
promoters. Mechanisms for binding include activator proteins to keep it in place, direct
binding to the DNA, or the interaction of TBP with other initiatory proteins [14]. Upon
examination of the RAI1 sequence, it was found that the promoter of RAI1 is a TATAless promoter. These types of promoters usually contain more transcription initiation
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sites and multiple binding sites for the transcription factor stimulating protein 1 (Sp1).
The function of Sp1 is to help in the formation of the preinitiation complex. Also
associated with TATA-less promoters is a sequence with high G/C content. TATA-less
promoters do not contain a TATA box, but require other transcription binding sites in
order to initiate transcription. The downstream core promoter element is also important in
the binding of the preinitiation complex in TATA-less promoters. It acts in conjunction
with the initiator element to bind the TFIID complex of transcription factors [16]. The
actual method of transcription initiation for TATA-less promoters varies for different
TATA-less promoters. A major goal of this project is to determine which of these
elements are present in the human RAI1 promoter and their function in the expression of
the RAI1 protein.
Summary. The purpose of this project is to characterize the RAI1 promoter. The
main methods used for characterizing the RAI1 promoter are the reporter gene assay and
5’RLM-RACE. The goal of the reporter gene assay is to determine if any RAI1
fragments contain promoter activity. The goal of 5’RLM-RACE is to determine the 5’
end of the RAI1 transcript. Studying the RAI1 promoter will help determine the normal
mechanisms for expression which may lead to insights into its role in causing SmithMagenis syndrome.
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METHODS
Cloning the 2.3kb RAI1 putative promoter construct. The purpose of cloning the
2.3kb RAI1 fragment was to clone the putative RAI1 promoter containing the upstream
response element. The predicted length of the longer putative promoter construct was
2.3kb. In order to clone the longer fragment of RAI1, PCR (polymerase chain reaction)
was used to amplify the fragment from genomic DNA. PCR was followed by gel
electrophoresis in order to visualize the PCR product.

PCR. The reaction mix used for the PCR reaction was: 1.0µL of HEK genomic DNA,
2.5µL of 10X PCR buffer, 1.5µL of 25mM MgCl2, 0.5µL of 10mM dNTP, 1.0 µL
(10µM) the forward primer SHE 599F, 1.0µL (10µM) of the reverse primer DZ2R,
17.25µL of dH20, and 0.25µL (5U/µL) of Taq DNA polymerase. The primers were
designed by Dr. Elsea and Dr. Zies for the RAI1 sequence from the publicly available
Human Genome Project. The forward primer sequence for SHE 599F was
5’TAAGTAGTTTGCCCAAAGCCACCC. The reverse primer sequence for DZ2R was
5’ACACCACACAAAGCAAGGACC. The amplification conditions for the PCR
reaction were 94°C for 5 minutes, 40 cycles of amplification at 94°C for 1 minute, 60°C
for 1 minute, 72°C for 3 minutes, and final extension at 72°C for 10 minutes.

Gel Electrophoresis. A 1% agarose gel was prepared by combining 600mg agarose in
60mL of 1X TAE buffer. The mixture was heated for approximately one minute in a
microwave until all the agarose dissolved. GelRed solution was added to the agarose gel
before it hardened at 1:10,000 for visualization of the DNA. Loading dye was added to
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the samples at ¼ of the volume of the sample before they were applied to the gel. A
100bp DNA ladder was used as the marker and was added to lane one for every gel run.
For each sample, 15-20µL was added to the other wells. The gel ran for one hour at 100
volts.

Development of shorter RAI1 putative promoter construct. A member of Dr. Elsea’s
lab was able to successfully clone a small fragment of RAI1. I was given this fragment in
order to perform further experiments on it. With this previously cloned fragment, I
developed a shorter fragment in order to remove potentially problematic ATG sequences.
It was cloned into a TOPO vector and then moved to the plasmid pGL3 (Promega, Inc.).
The methods used for developing the shorter plasmid were: restriction digest with the
restriction enzyme NcoI, gel electrophoresis (as previously described), gel extraction,
ligation, transformation, and plasmid purification.

Restriction Digest with NcoI. The following components were mixed in a
microcentrifuge tube: 10.5µL of dH20, 2.0µL of RE 10X buffer, 2.0µL of acetylated
BSA at 10µg/µL, and 5.0µL of DNA at 1µg/µL. The components were mixed by
pipetting and then 0.5µL of the restriction enzyme NcoI at 10U/µL (Promega, Inc) was
added bringing the total volume of the reaction to 20.0µL. The reaction was incubated
for one hour in a 37°C water bath.

Gel Extraction. This method was performed as described in the gel extraction kit from
Qiagen, Inc. After gel electrophoresis, the correct DNA band was removed from the
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agarose gel using a scalpel and then weighed in a pre-weighed 1.5mL microcentrifuge
tube. In order to dissolve the gel, 3 volumes of Buffer QG were added to the gel slice
and then the gel slice was incubated in a 50°C water bath for 10 minutes with intermittent
vortexing to aid in dissolving the gel. After the gel slice had dissolved, one volume of
isopropanol was added to the mixture. DNA was bound to the spin column matrix by
adding the mixture to a spin column, placing it inside a 2mL collection tube and
centrifuging for 1 minute at 13,000rpm. The bound DNA was washed by adding 0.5mL
of Buffer QG and centrifuging for 1 minute at 13,000rpm and then adding 0.75mL of
Buffer PE and centrifuging for an additional 1 minute at 13,000rpm. The flow-through
was discarded at each step and the spin column was centrifuged for an additional minute
to dry the column. The spin column was placed in a sterile 1.5mL microcentrifuge tube
for elution. The DNA was eluted by adding 50µL of elution buffer to the center of the
spin column followed by centrifugation for 1 minute.

Ligation. The following components were mixed in a 1.5mL microcentrifuge tube: 1µL
of gel extracted DNA, 1µL of 10X ligation buffer, 7µL of dH20, and 1µL of ligase at
10U/µL (Promega, Inc.). The reaction was incubated at 15°C overnight in the
thermocycler.

Transformation. Competent DH5α cells (Invitrogen, Inc) from the -80°C freezer were
thawed on ice before use. Then 1µl of the ligation reaction from the previous step was
added to the cells and gently mixed with the tip of a pipette. The cells were incubated on
ice for 30 minutes followed by heat shock for 20 seconds in a 42°C water bath. The cells
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were then placed back on ice for 2 minutes. Preheated LB broth (950µL) was added to
the cells and placed on a shaker for 45 minutes in a 37°C incubator. The cells were then
centrifuged for a few seconds in order to pellet the cells. The majority of the supernatant
was removed (~825µL). The cells were resuspended in the remaining media and 100µL
was plated on LB plus ampicillin plates using sterile technique. The plates were
incubated overnight at 37°C.

Plasmid Purification. This method was performed as described in the plasmid DNA
miniprep kit from Qiagen, Inc. Bacterial colonies were selected from the LB-Amp plates
from the transformation and grown in 3mL of liquid LB-Amp overnight. The 3mL
bacterial cultures were pelleted using a microcentrifuge and the supernatant was
removed. The pellet was resuspended using 250µL of resuspension buffer (Buffer P1).
Following addition of Buffer P1, 250µL of lysis buffer (Buffer P2) was added and then
mixed by inverting the tube. Then, 350µL of neutralization buffer (Buffer N3) was
added and mixed by inverting the tube. The tubes were centrifuged for 10 minutes at
15,682 RCF. In order to bind the DNA, the supernatant was applied to the spin column
and then centrifuged for 30-60 seconds. The DNA was washed by adding 0.5mL of
Buffer PB to the spin column and centrifuging for 1 minute and then adding 0.75mL of
Buffer PE and centrifuging for 1 minute at 15,682 RCF. The flow-through was discarded
at each step and the spin column was centrifuged for an additional minute in order to dry
the column. In order to elute the DNA, 50µL of elution buffer was added to the center of
the spin column that was placed in a 1.5mL microcentrifuge tube. The column was
incubated for 1 minute at room temperature and then centrifuged for 1 minute at 15,682
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RCF. The concentration of the new plasmid (RAI1 short) was quantified by measuring
the absorbance of the solution at 260nm and 280nm.

Luciferase Reporter Gene Assay. The luciferase reporter gene assay was performed on
RAI1 long plasmid and RAI1 short plasmid in order to detect activity of the RAI1
promoter using a luminometer. The reporter gene constructs were transfected into
HEK293 cells. After 24 hours, the cells were lysed and mixed with appropriate reporter
gene substrates. The reporter gene activity was detected using the luminometer located at
the Medical College of Virginia (MCV).

Transient Transfection. Three plasmids of interest were transfected into the mammalian
cell line HEK293. The RAI1 long (original RAI1 plasmid) and RAI1 short plasmids were
both cotransfected with the control plasmid pSV-βgal. Before beginning the assay,
HEK293 cells were grown in 500µL of medium (DMEM+10%FBS without antibiotics)
per well of a 12-well plate in order for them to be 90-95% confluent (about 0.5-2 x 10^5
cells) at the time of transfection. For each plasmid sample, 1.6µg of DNA was mixed
with 100µL DMEM with no serum. Separately, 4uL of Lipofectamine 2000 (Invitrogen,
Inc.) was mixed with 100µL DMEM and incubated for 5 minutes. After the 5 minute
incubation, the diluted DNA was added to the diluted Lipofectamine 2000 bringing the
total volume to 200µL. The solution was mixed and incubated for 20 minutes at room
temperature. Then, the 200µL Lipofectamine/DNA complexes were added dropwise to
each well containing cells. The contents were mixed by gently rocking it back and forth
before placing it in a 37°C CO2 incubator overnight.
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Luciferase Cell Culture Lysis. The transfected cells were lysed using 1X reporter lysis
buffer (Promega). First, the growth medium from the cells was removed using a pipette.
Then the cells were washed with 200µL PBS (phosphate buffered saline) followed by the
addition of 150µL of 1X lysis buffer to each well ensuring that the bottom of each well
was covered. The lysed cells were scraped off the bottom of the well using a scraper and
transferred to a 1.5mL microcentrifuge tube on ice using a pipette. Each tube was
vortexed for 10-15 seconds and then centrifuged at 12,000 RCF for 15 seconds at room
temperature. The supernatant was transferred to a new tube and the cell lysates were
stored at -80°C.

Reporter Gene Assay. First, 20µL of each prepared cell lysate was added to two wells of
a solid white 96-well plate. Then 100µL of steady-glo luciferase (Promega, Inc.) was
added to half of the wells and 70µL of a 1:100 dilution of β-gal substrate (Applied
Biosystems) and buffer mix was added to the other half of the wells. After incubating for
30 minutes, 100µL of the β-gal accelerator was added to the designated β-gal wells and
activity was measured using the luminometer (Wallac 1420). Within those 30 minutes,
luciferase activity of the steady-glo luciferase samples was measured using the
luminometer. Each sample was run in duplicate.

β-galactosidase Reporter Gene Assay. The β-gal reporter gene assay was performed in
place of the luciferase reporter gene assay in order to work out technical difficulties with
the transient transfection assay and to use equipment available at UMW. The β-gal
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reporter gene assay uses color change, instead of light, as an indicator of promoter
activity. Transient transfection was performed 24 hours before beginning the β-gal
reporter gene assay.

Preparation of Lysates. Both 6-well and 12-well plates were used for growing cells for
this assay. The growth medium was carefully removed from the cells using a pipette.
The cells were then washed twice with 1X PBS. For the 6-well plate, 300µL of 1X RLB
(reporter lysis buffer) was added to each well. For the 12-well plate, 200µL of 1X RLB
was added to each well. After ensuring complete coverage of the cells by the lysis buffer,
the cells were incubated for 15 minutes at room temperature rocking the dish every 3
minutes. The lysed cells were then scraped to the lower edge of the plate, transferred to a
clean 1.5mL microcentrifuge tube using a pipette, and immediately placed on ice. Then
the cells were vortexed for 10-15 seconds and centrifuged in a microcentrifuge at 4°C for
2 minutes at 15,682 RCF. The supernatant was transferred to a new tube and stored at
-80°C until ready to proceed to the standard assay.

Standard Assay. For the assay, 150µL of each cell lysate was transferred to a new 1.5mL
microcentrifuge tube followed by the addition of 150µL of Assay 2X Buffer to each tube.
The samples were mixed by vortexing them for a few seconds and then incubated at 37°C
for 30 minutes or until the reaction turned a faint yellow color. In order to stop the
reactions, 500µL of 1M sodium carbonate was added to each tube. The reactions were
vortexed briefly before their absorbance was read at 420nm.
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Generation of Standard Curve. A 1:10,000 dilution stock of β-galactosidase was
prepared in 1X RLB (reporter lysis buffer). Using this stock, seven β-gal standards were
made as shown in the following table.
Table 2. β-gal standards for the β-gal reporter gene assay.
β-galactosidase Standard
Volume of 1:10,000 stock
Volume of 1X RLB (µL)
(milliunits)
(µL)
0
0
150
1.0
10
140
2.0
20
130
3.0
30
120
4.0
40
110
5.0
50
100
6.0
60
90
The total volume for each standard used in the assay was 150µL.

Using the same procedure as for the standard assay, 150µL of Assay 2X Buffer was
added to each standard and incubated for 37°C for 30 minutes. The reactions were
stopped by adding 500µL of 1M sodium carbonate. The reactions were vortexed briefly
before their absorbance was read at 420nm.

5’RLM-RACE. 5’RLM-RACE (Ambion, Inc.), or RNA Ligase Mediated Rapid
Amplification of cDNA Ends, was used in order to determine the 5’ end of the RAI1
transcript. RNA was isolated from HEK293 cells for this procedure.

Cell Lysis and RNA Isolation. This method was performed as described in the
RNAqueous kit by Ambion, Inc. HEK cells were grown to confluency in a 100mm
culture dish. The growth medium was removed from the dish and the cells were washed
with a 5mL of PBS. Then, 1400µL of lysis buffer was added to the dish. The cells were
scraped using a scraper and two 700µL aliquots were collected in 1.5mL microcentrifuge
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tubes. The cell lysates were vortexed and stored at -80°C until RNA isolation was
performed. An equal volume of 64% ethanol was added to the lysates and mixed. The
lysate/ethanol mixture was added to the filter cartridge in a collection tube and then
centrifuged for 15 seconds-1 minute at 13,000 RCF. The previous two steps were
repeated until all the sample had been drawn through the filter cartridge. In order to wash
the DNA, 700µL of wash solution #1 was applied to the filter cartridge and then
centrifuged. As an additional wash step, 500µL of wash solution #2/3 was applied to the
filter cartridge and centrifuged followed by the addition and centrifugation of another
500µL of wash solution #2/3. In order to dry the column, the sample was centrifuged
again. The flow-through was discarded after each step. The first step for eluting the RNA
was to pipet 40-60µL of preheated elution solution (about 70-80°C) to the center of the
filter placed in a 1.5mL microcentrifuge tube and then centrifuge for 30 seconds at room
temperature (13,000 RCF). Then a second aliquot (10-60µL) of preheated elution
solution was added to the center of the filter and re-spun for 30 seconds. To complete
RNA elution, a third 10-60µL aliquot of elution solution was added and centrifuged in
the same manner as the first step. The RNA samples were stored at -80°C until further
use.

CIP and Termination. The purpose of treating the RNA with Calf Intestine Alkaline
Phosphatase (CIP) is to remove the 5’ phosphate from degraded RNA. The following
components were mixed for the treatment with CIP step: 10µg (standard reaction) or 1µg
(small reaction) of RNA (in XµL), 2µL of 10X CIP Buffer, 2µL of CIP, and nucleasefree water up to 20µL. The reaction was then mixed, centrifuged briefly, and incubated
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for one hour at 37°C. In order to terminate the CIP reaction, the following components
were added to the CIP reaction: 15µL of ammonium acetate solution, 115µL of
nuclease-free water, and 150µL of acid phenol:chloroform. The reaction was vortexed
thoroughly and centrifuged for 5 minutes at 15,000 RCF in a microcentrifuge. The top
layer (aqueous layer) was transferred to a new tube. Then 150µL of chloroform was
added to the sample, vortexed thoroughly, and centrifuged for 5 minutes at 15,000 RCF
in a microcentrifuge. The top layer (aqueous layer) was transferred to a new tube.

Precipitation and Resuspension of RNA. According to the protocol from Ambion, Inc.,
the first step in precipitation of RNA was to add150µL of isopropanol to the sample,
vortex thoroughly, and chill on ice for 10 minutes. Then the sample was centrifuged for
20 minutes at maximum speed in a microcentrifuge. The pellet was washed by adding
0.5mL cold 70% ethanol and then centrifuged for 5 minutes at 15,000 RCF. The ethanol
was removed carefully and the pellet was dried. The resuspension step differed for the
standard reaction and the small reaction. Both of these reactions were performed and are
differentiated below. For the standard reaction, the pellet was resuspended in 11µL of
Nuclease-free water. For the small reaction, the pellet was resuspended in 4µL of 1X
TAP Buffer.

Treatment with TAP. The purpose of the fifth step, treatment of RNA with Tobacco Acid
Pyrophosphatase (TAP), is to remove the 5’cap from the HEK RNA. For this step, the
following components were mixed for the standard reaction: 5µL of CIP’d RNA, 1µL of
10X TAP buffer, 2µL of TAP, 2µL of nuclease-free water. The following components
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were mixed for the small reaction: 4µL of CIP treated RNA and 1µL of TAP. The
reactions were then mixed, centrifuged briefly, and incubated for one hour at 37°C.

Ligation of 5’RACE Adapter. The purpose of the ligation reaction is to ligate the 5’RACE
adapter oligonucleotide to the 5’ end of the RNA. For the standard reaction of this step,
the following components were mixed: 2µL of CIP/TAP treated RNA, 1µL of the
5’RACE adapter (3µg/µL), 1µL of 10X RNA ligase buffer, 2µL of T4 RNA Ligase
(2.5U/µL), and 4µL of nuclease-free water. The following components were mixed for
the small reaction: 5µL of CIP/TAP treated RNA, 1µL of the 5’RACE adapter, 1µL of
10X RNA ligase buffer, 2µL of T4 RNA ligase (2.5U/µL), and 1µL of nuclease-free
water. The reactions were mixed gently, centrifuged briefly, and incubated for one hour
at 37°C.

Reverse Transcription. For the reverse transcription reaction, the following components
were assembled in a 1.5mL microcentrifuge tube on ice: 2µL of the ligated RNA, 4µL
10µM dNTP mix, 2µL of 50µM random decamers, 2µL of 10X RT buffer, 1µL of
10U/µL RNase inhibitor, 1µL of M-MLV reverse transcriptase, and 8µl of nuclease-free
water. The reaction was mixed gently, centrifuged briefly, and incubated for one hour at
42°C.

Nested PCR for 5’RLM-RACE. The PCR for the 5’RLM-RACE consisted of two PCR
reactions: an outer PCR followed by an inner PCR. For the outer PCR, the following
components were mixed in a PCR tube: 1µL of the reverse transcription reaction from
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the previous step, 5µL of 10X PCR buffer, 4µL of 10µM dNTP mix, 2µL of the 5’RACE
gene specific outer primer at 10µM (p40-5’TGCGGGTTATAATAGTCCTTGGCG),
2µL of the 5’RACE outer primer, 36µL of nuclease-free water, and 0.25µL of 5U/µL
thermostable DNA polymerase. The cycling profile for the PCR reaction was 94°C for 3
minutes, 35 cycles of 94°C for 30 seconds, 60°C for 30 seconds, 72°C for 30 seconds,
and final extension at 72°C for 7 minutes. For the inner PCR reaction, the following
components were mixed in a PCR tube: 2µL of the outer PCR product, 5µL of 10X PCR
buffer, 4µL of dNTP mix, 2µL of the 5’RACE gene specific inner primer at 10µM (p395’TTCTCTAGGCGTGATGTTTCCTGC), 2µL of the 5’RACE inner primer, 35µL
nuclease-free water, and 0.25µL of 5U/µL thermostable DNA polymerase. The cycling
profile for the inner PCR was the same as for the outer PCR. Inner PCR was followed by
gel analysis of the PCR products using gel electrophoresis as previously mentioned.

TOPO Cloning. The TOPO cloning reaction was used in order to insert the PCR product
into a vector suitable for sequencing (Invitrogen, Inc.). The following components were
added together and mixed gently: 2µL of fresh PCR product, 1µL of salt solution, 2µL of
water, and 1µL of the TOPO vector. The reaction was incubated for 5 minutes at room
temperature and was placed on ice before proceeding to transformation. The TOPO
clone was transformed using the method of transformation previously mentioned but used
One Shot TOP10 chemically competent cells. Following transformation, the plasmid
was purified using the plasmid purification method previously mentioned. After plasmid
purification, the plasmid was sent off to AGGT, Inc. for sequencing.
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RESULTS
Cloning the 2.3kb RAI1 Fragment. The purpose of cloning a longer RAI1 fragment was
to include the potential retinoic acid response element 1 as well as additional DNA that
may serve as part of the RAI1 promoter. The primers used for the PCR reaction were the
forward primer SHE599 and the reverse primer DZ2. Primer SHE599 is located
upstream of the putative retinoic acid response element 1 and primer DZ2 is located
downstream of RAI1 exon 1 (Figure 1A). Figure 1B shows a representative 1% agarose
gel of the PCR reactions. The experimental reactions are in lanes 2 and 3. Multiple
bands were seen for each sample with the largest molecular weight band at about 1000bp.
This was not the result we were expecting since we were expecting a band at 2.3kb.

Development of a Shorter RAI1 Plasmid. The RAI1 fragment I received from MCV was
thought to contain several ATGs, or start codons, within intron 1. These potential start
codons might pose a problem for the translation of the luciferase reporter gene when
performing the reporter gene assay. Therefore, the restriction enzyme NcoI was used to
cut out RAI1 intron 1. The restriction sites for NcoI are immediately upstream of intron 1
and at the translation start site for pGL3 (Figure 2A). Figure 2B shows a representative
1% agarose gel of the NcoI digest. The top band from the restriction digest is about
6550bp. The bottom band from the restriction digest is 326bp and represents the piece of
DNA cut out from pGL3 (RAI1 intron 1). Figure 2C shows a representative 1% agarose
gel of the RAI1 long plasmid (lane 2) and the RAI1 short plasmid (lane 3) after restriction
digest with NcoI. Since the RAI1 short plasmid was already digested with NcoI, there
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was only one band present at about 6550bp. The long RAI1 plasmid had two bands
present with the smaller band being the fragment cut out by NcoI.

RAI1 Promoter Constructs. All RAI1 promoter constructs were inserted in front of the
luciferase gene in the pGL3 plasmid. The RAI1 long promoter construct, containing the
RAI1 intron 1, is shown in Figure 3A and the RAI1 short promoter construct, without
RAI1 intron 1, is shown in Figure 3B. The control plasmid pGL3, in which there was no
insertion of the putative RAI1 promoter in front of the luciferase gene, is shown in Figure
3C.

Representative Data from Initial Reporter Gene Assay. The RAI1 long plasmid, RAI1
short plasmid, and pGL3 were cotransfected with the control plasmid pSV-β-Gal. The
RAI1 long and RAI1 short plasmids were run in quadruplicate whereas the pGL3 plasmid
was run in triplicate. In addition, each sample was run in duplicate for the luciferase
substrate and for the β-gal substrate (Table 3). For the RAI1 long plasmid and the RAI1
short plasmid, the β-gal numbers were higher than the luciferase numbers.

β-gal Reporter Gene Assay. The β-gal assay was run in quadruplicate with two different
concentrations of DNA: 0µg of DNA as a control and 1µg of DNA as the experimental.
Assay results were read on a spectrophotometer and the absorbance numbers at 420nm
for each concentration of DNA. As shown in Table 4, the absorbance numbers for 1µg of
β-gal plasmid were higher than the absorbance numbers for no β-gal plasmid.
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Reporter Gene Assay Showing No Activity. The reporter gene assay was run with
different concentrations of RAI1 short and RAI1 long plasmids (1µg vs. 2µg). Each
combination of concentration/plasmid was run in duplicate. The light unit values for
each plasmid/concentration combination are shown in Table 5. In general, the β-gal
numbers were higher than the luciferase numbers. In addition, both the β-gal and
luciferase numbers were consistent across the board indicating the transfection was
working.

Reporter Gene Assay with DZ23. The reporter gene assay was run in duplicate with the
plasmid DZ23, which has known promoter activity, the RAI1 long plasmid, RAI1 short
plasmid, and pSV-β-gal. Table 6 shows the light unit data from each of the plasmids for
the luciferase substrate samples and the B-gal substrate samples. The data shows that
plasmid DZ23 has luciferase activity whereas the other three plasmids do not have any
luciferase activity.

5’RLM-RACE. The 5’RLM-RACE protocol was used in order to amplify the 5’ end of
RNA from RAI1. A representative 1% agarose gel from one of the two 5’RLM-RACE
procedures conducted, is shown in Figure 5. Lane 2 is from the outer PCR and lanes 3
and 4 are from the inner PCR. The bands are all less than 25bp strongly indicating they
were excess primers and that I did not successfully amplify the 5’ end of the RAI1
transcript.
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Figure 1. Cloning the 2.3kb RAI1 fragment. A) Position of the primers used for cloning
the 2.3kb fragment. The blue box represents the retinoic acid response element 1 and the
green box represents RAI1 exon 1. The green arrow represents the transcription start site
for RAI1. SHE599 was the forward primer used in PCR located upstream of the Retinoic
Acid Response Element 1. DZ2 was the reverse primer used located directly downstream
of RAI1 exon 1. B) A representative agarose gel showing the PCR products. Lane 1 is
the DNA ladder whereas lanes 2 and 3 are the PCR product samples.
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A)

23130bp
9416bp
6557bp
4361bp

725bp
570bp

B)

C)

Figure 2. Development of Shorter RAI1 Plasmid. A) NcoI restriction sites. NcoI has two
restriction sites represented by the red line and the red arrow. One restriction site cuts the
DNA at the start of RAI1 intron 1 (indicated by the thick blue line) and the second
restriction site cuts the DNA at the translation start site for pGL3 (the red arrow). The
dashed lines represent pGL3. The blue boxes within intron 1 represent possible ATGs or
start codons for translation of RAI1. The black arrow represents the transcription start
site for RAI1. B) A representative gel following restriction digest with NcoI. Lane 1 is
the DNA ladder and lane 2 is the sample. The bottom band of the sample lane is the
DNA fragment removed from NcoI and is 326bp in length. C) A representative gel of
the restriction digests of RAI1 short and RAI1 long plasmids. Lane 1 is the DNA ladder.
Lane 2 is the restriction digest with NcoI of the RAI1 long plasmid. Lane 3 is the
restriction digest of RAI1 short plasmid.
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Figure 3. RAI1 Promoter Constructs. The gray box represents the putative RAI1
promoter. The black box with LUC represents the luciferase gene. A) The red line
represents the sequence of DNA that was excised using the restriction enzyme Nco1.
This fragment is the RAI1 long fragment. B) This fragment is the RAI1 short fragment
which has the red line removed. C) This fragment represents the control plasmid pGL3
with no RAI1 promoter fragment inserted in front of the luciferase gene.

Table 3. Representative data of luciferase reporter gene assay using RAI1 long plasmid,
RAI1 short plasmid, and pGL3.
RAI1 long plasmid
RAI1 short plasmid
pGL3 plasmid
21
21
24
174
269 494 130 55
209 72
LUC 18
32
30
28
19
167
247 453 157 40
192 67
401 323 3432 322
387 1583 288 180 495 88
β-gal 611
700
406 325 3526 391
474 38
27
35
487 33
All three plasmids were cotransfected with pSV-βgal. Quadruplets were run of the RAI1long plasmid and the RAI1-short plasmid. The pGL3 plasmid was run in triplicate. The
first two rows represent duplicate samples that had the luciferase substrate added (LUC).
The last two rows represent duplicate samples that had the β-gal substrate added. All
numbers shown are in light units (LU).
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Table 4. Representative data from the β-gal reporter gene assay.
Amount of DNA
Absorbance at 420nm
0µg
0.141
0.153
0.157
0.154
1µg
0.269
0.264
0.299
0.219
The assay was done in quadruplet for each concentration of DNA.

Table 5. Raw data of the reporter gene assay using different concentrations of the RAI1
short and RAI1 long plasmids.
1ug RAI1-long
2ug RAI1- 1ug RAI1-short
2ug RAI1(LU)
long (LU)
(LU)
short (LU)
84
86
73
58
68
87
49
LUC
3599
3870
2863
1710 1549
2499
2201
β-gal
Duplicates were run for each concentration/plasmid combination.
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Table 6. Raw data of reporter gene assay using plasmid DZ23 as a positive control
β-gal
DZ23
RAI1 short
RAI1 long
71
85
1139
1042
76
86
61
70
LUC
3277
4000
3224
2991
3653
3364
3387
4354
β-gal
. The reporter gene assay was also performed on β-gal plasmid and both RAI1 plasmid
constructs. All numbers shown are in light units. Duplicates were run for each plasmid.

50bp
25bp

Figure 5. Representative 1% agarose gel of 5’RLM-RACE. Lane 1 represents the DNA
ladder. Lane 2 represents the PCR product resulting from the outer PCR. Lanes 3 and 4
represent PCR products resulting from the inner PCR
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DISCUSSION
Cloning the 2.3kb RAI1 Fragment. As shown in Figure 1A, the expected length
of the RAI1 fragment from PCR was 2.3kb. Several attempts to clone the 2.3kb fragment
were conducted, varying PCR conditions each time such as the concentration of MgCl2
and the temperature cycling profile. However, there were no bands present at 2.3kb for
any of the attempts. Figure 1B shows the best result that was obtained from the PCR.
The lack of bands at 2.3kb indicates that the primers did not work in cloning the longer
RAI1 fragment. These data, along with additional attempts using alternative primers (not
shown), suggest that the published sequence of the RAI1 upstream region from the human
genome project may be inaccurate.
Reporter Gene Assay. The restriction digest with NcoI was successful in cutting
out the RAI1 intron 1. Removing RAI1 intron 1 from the RAI1 promoter construct would
eliminate the hypothetical possibility that the start codons present in intron 1 would
interfere with translation of the luciferase gene. This would increase the chances of the
reporter gene assay being successful.
The results from the first reporter gene assay were somewhat discouraging. In
general, the β-gal numbers were larger than the numbers for the luciferase samples which
was to be expected (Table 3). However, we were expecting numbers in the 1000s and
10000s for both the luciferase and β-gal samples. The luciferase sample numbers were
generally higher for RAI1 short plasmid than for the RAI1 long plasmid. This indicated
that there was a possibility that the NcoI restriction digest did make a difference in the
amount of luciferase protein produced. The highest luciferase number was only 494 light
units for RAI1 short plasmid and 32 light units for the RAI1 long plasmid. The low
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luciferase numbers were attributed to a problem with the transient transfection assay
efficiency.
In order to determine transfection efficiency and to use equipment available to at
UMW, the β-gal reporter gene assay, that was spectrophotometric rather than
luminescent, was performed. This assay involved transfection with pSV-β-gal, cell lysis,
and measurement of promoter activity by measuring a color change in a
spectrophotometer. The β-gal reporter gene assay showed higher absorbance numbers
when pSV-β-gal plasmid was transfected versus when no pSV-β-gal was transfected
(Table 3). This indicated that the cells were transiently transfected, and allowed for the
elimination of transfection as a possible source of error. Since the transfection was
working, this suggested to us that the low luciferase numbers observed in the first
luciferase reporter gene assay were from background noise.
Since the conditions for the transfection assay were worked out, another luciferase
reporter gene assay was performed (Table 4). Once again, the β-gal numbers were larger
than the luciferase numbers, as expected. When comparing the first reporter gene assay
(Table 2) to the current attempt, the β-gal numbers were improved indicating that the
transfection was working well. Furthermore, the amount of plasmid transfected (1µg vs.
2µg) did not have an effect on the degree of luminescence in the luciferase samples.
These results further led us to believe that the luciferase activity that was detected was
due to background noise. The presence of low luciferase activity indicated one of two
possibilities. There was either no promoter activity in the RAI1 promoter constructs or
the luciferase part of the assay wasn’t working.
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In order to determine which of these possibilities was correct, the luciferase
reporter gene assay was performed with plasmid DZ23 which has known promoter
activity. In addition, the assay was performed with RAI1 long plasmid, RAI1 short
plasmid, and β-gal plasmid (as a control). Plasmid DZ23 had significantly higher
luminescence compared to the other three plasmids. This confirmed that DZ23 has
promoter activity, but that the two RAI1 promoter constructs do not. Therefore, the RAI1
fragments we used did not contain the RAI1 promoter as we initially thought. One reason
why we did not have any promoter activity in the RAI1 promoter constructs is that the
sequence for the location of the 5’ end of the RAI1 gene obtained from the Human
Genome Project (from which these constructs were derived) may be inaccurate. If the
sequence for the RAI1 promoter is incorrect, this would also explain why there was
difficulty in amplifying the 2.3kb fragment.
5’RLM-RACE. The 5’ end of the RAI1 sequence was originally obtained through
the Human Genome Project. However, upon investigation of the origin of the sequence,
it was discovered that the methods used to identify the 5’ end weren’t as accurate as
5’RLM-RACE [12]. In order to determine the true end of the RAI1 transcript, 5’RLMRACE, a more precise method of determining the 5’ end, was used. The 5’RLM-RACE
protocol is also the first step in trying to determine the location of the RAI1 promoter
experimentally. The purpose of 5’RLM-RACE was to amplify the 5’ end of the RNA of
RAI1. The sequence determined from 5’RLM-RACE could then be aligned with the
Human Genome sequence in order to develop primers to amplify the region of DNA
directly upstream of the 5’ end. In theory, the RAI1 promoter would be located upstream
of the 5’ end of the RNA of RAI1 allowing for the RAI1 promoter to be successfully
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cloned. The results from the 5’RLM-RACE indicate that the bands present are just
remains of the primers used. Experiments to date were unsuccessful in amplifying the 5’
end of RAI1. Time constraints prevent troubleshooting this lengthy process.
Summary. The purpose of this project was to characterize the RAI1 promoter
using the reporter gene assay. In addition to performing the reporter gene assay, I
attempted to clone the 2.3kb fragment of RAI1. Unfortunately, the attempts I made at
cloning the 2.3kb fragment were unsuccessful so that portion of the project had to be
abandoned. I then switched to working with a fragment of RAI1 previously cloned by a
member of Dr. Elsea’s laboratory. I used this fragment in order to develop a shorter RAI1
promoter construct for use in the reporter gene assay. From the results of the multiple
reporter gene assays that I performed, I concluded that the RAI1 promoter constructs I
had did not contain any promoter activity. Therefore, the RAI1 fragments that I had did
not contain the RAI1 promoter indicating that the sequence for the RAI1 promoter is
incorrect. Since the fragment I was working off of was developed from the sequence of
RAI1 from the Human Genome Project, I turned to looking at determining the location of
the RAI1 promoter experimentally. The first step in determining the promoter
experimentally was 5’RLM-RACE which amplifies the 5’ end of the RNA of RAI1. Both
trials of 5’RLM-RACE were unsuccessful in amplifying the 5’ end.
The experiments that I have performed throughout the course of this project have
established a stepping stone for the next person that takes over my project. Due to the
work I did with the reporter gene assay, we now know that the RAI1 fragments previously
cloned did not contain the RAI1 promoter. Because of that finding, we can now move on
to finding the actual location of the RAI1 promoter.
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